Core Viewpoint - Weijian International Holdings Limited has submitted an application for H-share listing on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1] Group 1: Company Overview - Weijian International is a comprehensive pharmaceutical company focused on the treatment of kidney and blood diseases, with a diverse product portfolio that also extends to respiratory and skin diseases [2] - The company has the largest number of commercialized original research drugs for kidney diseases among Chinese pharmaceutical companies, with a product portfolio that includes over 20 commercialized drugs and one candidate drug [2] Group 2: Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 724 million, RMB 887 million, RMB 902 million, and RMB 798 million respectively, showing significant revenue fluctuations [2][3] - Net profit figures for the same periods were approximately RMB -93 million, RMB -17 million, RMB 8.6 million, and RMB 24 million, indicating notable volatility in profitability [2][3] Group 3: Client Base and Revenue Concentration - The main clients of Weijian International include pharmaceutical product distributors and companies seeking promotional services, with the top five clients contributing approximately RMB 435 million, RMB 487 million, RMB 539 million, and RMB 487 million to total revenue in the respective years, accounting for 60.2%, 54.8%, 59.8%, and 61.1% of total revenue [4] - The revenue from the largest client was approximately RMB 109 million, RMB 160 million, RMB 170 million, and RMB 205 million, representing 15.0%, 18.0%, 18.9%, and 25.7% of total revenue [4] Group 4: Strategic Developments - In September 2024, Weijian International completed the acquisition of Xiehe Qilin China, gaining exclusive rights to develop, produce, and commercialize five original research drugs, along with approximately 43,000 square meters of production facilities and self-production capabilities [4] - The company may face challenges in successfully identifying, discovering, acquiring, licensing, or developing new candidate products to maintain its product pipeline [4]

据港交所11月7日披露，维健国际控股集团有限公司(维健医药)向港交所主板提交上市申请书，华泰国际为其独家保荐人。据招股书，维健医药是一家专注 于肾脏及血液疾病治疗的中国领先综合性制药企业，拥有集药物开发、生产及商业化于一体的综合实力。维健医药致力于通过提供创新且有价值的治疗方 案，解决肾脏与血液疾病及其他重大疾病治疗领域尚未满足的巨大临床需求。 招股书提到，维健医药已打造多元且差异化的产品组合，广泛覆盖肾脏与血液疾病领域，并延伸至呼吸系统及皮肤疾病等其他重大疾病领域。根据灼识咨询 的资料，截至最后实际可行日期，维健医药的产品组合涵盖六种肾脏药物，是中国制药企业中治疗肾脏疾病商业化原研药数量最多的企业。 ...

智通财经APP获悉，据港交所11月7日披露，维健国际控股集团有限公司(维健医药)向港交所主板提交上市申请书，华泰国际为其独家保荐人。据招股书，维 健医药是一家专注于肾脏及血液疾病治疗的中国领先综合性制药企业，拥有集药物开发、生产及商业化于一体的综合实力。维健医药致力于通过提供创新且 有价值的治疗方案，解决肾脏与血液疾病及其他重大疾病治疗领域尚未满足的巨大临床需求。 招股书提到，维健医药已打造多元且差异化的产品组合，广泛覆盖肾脏与血液疾病领域，并延伸至呼吸系统及皮肤疾病等其他重大疾病领域。根据灼识咨询 的资料，截至最后实际可行日期，维健医药的产品组合涵盖六种肾脏药物，是中国制药企业中治疗肾脏疾病商业化原研药数量最多的企业。 ...